Want to join the conversation?
Biopharma company $GILD said 2 Phase 3 trials, Studies 108 and 110, evaluating once-daily TAF 25 mg in adults with HBeAg-negative and HBeAg-positive chronic HBV infection met their primary endpoints of non-inferiority versus Viread 300 mg. TAF also showed improved renal and bone lab safety parameters versus Viread.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$